These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20864811)

  • 41. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
    Eke I; Cordes N
    Radiother Oncol; 2011 Jun; 99(3):279-86. PubMed ID: 21704406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical experience with monoclonal antibodies to epidermal growth factor receptor.
    Calvo E; Rowinsky EK
    Curr Oncol Rep; 2005 Mar; 7(2):96-103. PubMed ID: 15717942
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
    Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
    J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.
    Kjær I; Lindsted T; Fröhlich C; Olsen JV; Horak ID; Kragh M; Pedersen MW
    Mol Cancer Ther; 2016 Jul; 15(7):1614-26. PubMed ID: 27196767
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
    Li X; Lu Y; Liang K; Hsu JM; Albarracin C; Mills GB; Hung MC; Fan Z
    Oncogene; 2012 Oct; 31(40):4372-83. PubMed ID: 22231447
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
    Brand TM; Iida M; Wheeler DL
    Cancer Biol Ther; 2011 May; 11(9):777-92. PubMed ID: 21293176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
    Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
    Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
    Takata M; Chikumi H; Miyake N; Adachi K; Kanamori Y; Yamasaki A; Igishi T; Burioka N; Nanba E; Shimizu E
    Cancer Biol Ther; 2012 Apr; 13(6):369-78. PubMed ID: 22313637
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
    Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.
    Lin JF; Lin YC; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
    Drug Des Devel Ther; 2016; 10():1501-13. PubMed ID: 27143856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chloroquine promotes gefitinib‑induced apoptosis by inhibiting protective autophagy in cutaneous squamous cell carcinoma.
    Ou C; Liu H; Ding Z; Zhou L
    Mol Med Rep; 2019 Dec; 20(6):4855-4866. PubMed ID: 31638204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance?
    Dreier A; Barth S; Goswami A; Weis J
    Tumour Biol; 2012 Feb; 33(1):85-94. PubMed ID: 21986964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.